

Curriculum Vitae
Giovannino Silvestri, Biologist, Ph.D.
Research Associate, Institute of Human Virology,
School of Medicine
University of Maryland Baltimore

Date May 5, 2021

Contact Information

Business Address: Institute of Human Virology
725 West Lombard Street, S-333
Baltimore, 21201

Business Phone Number: (410) 706-6168

Fax: (410) 706-6168

Email: Gsilvestri@ihv.umaryland.edu

Foreign Languages: English (Fluently), Italian (Native Language)

Web page: <http://www.medschool.umaryland.edu/profiles/Silvestri-Giovannino/>

Education

2003-2006 B.S., Biology, University of Calabria, Italy.

2006-2009 M.S., Biology, University of Calabria, Italy (Magna cum Laude).

2010-2013 Ph.D., Cellular and Molecular Pathology and Biology, University of Verona, Italy
Thesis Advisor – Dr. Claudio Sorio.
“Biochemical and functional characterization of the oncosuppressor gene Protein Tyrosine Phosphatase Receptor Gamma”.

Personal Statement

Research Associate in the lab of Dr. Chozha Rathinam, Ph.D. I have a broad background in molecular cancer biology with specific training in chronic myelogenous leukemia (CML). I received my Ph.D. from University of Verona, Italy, in Molecular and Cellular Biology and Pathology. There I gained expertise in leukemia disease progression and phosphatases signaling. During my Ph.D. studies, I assessed the role of the PTPRG phosphatase in CML. In Dr. Perrotti's lab, as a Post-Doctoral Fellow, I have focused my efforts in identifying novel mechanisms of stemness in CML. I have studied the role of microRNAs and non-coding RNAs in the cross-talk between leukemic stem, stromal and immune cells in order to find novel pathways that can be used for the rational development of drugs able to selectively kill CML leukemia stem cells and also other type of leukemias without harming normal hematopoiesis or exerting side effects on other organs. My contribution in science has been published in peer reviewed journal articles, including papers in Blood Cancer Discovery, Frontiers in Immunology, Analyst, Oncotarget, Hematologica and Current Drug Targets. Currently, my research interest is to define aberrant molecular pathways that cause transformation of normal stem cells to cancer stem cells and lately the role of stem cells in response to SARS-CoV-2 infection.

Post Graduate Education and Training

2005-2006 Internship in Anatomy Pathology, Centro Sanitario, University of Calabria, Italy.
2008-2009 M.S. student, Biology, University of Calabria, Italy
2010-2013 Ph.D. student, Mol. and Cellular Bio. and Pathol., University of Verona, Italy.
2013-2018 Post-Doctoral Fellow, Mol. Oncology, University of Maryland Baltimore, USA.
2018-2018 Research Associate, Program in Oncology, University of Maryland Baltimore, USA.
2019-pres. Research Associate, IHV, University of Maryland Baltimore, USA.

Academic Appointments

2013-2018 Post-Doctoral Fellow, Mol. Oncology, University of Maryland Baltimore, USA.
2018-2018 Research Associate, Program in Oncology, University of Maryland Baltimore, USA.
2019-pres. Research Associate, IHV, University of Maryland Baltimore, USA.

Professional Society Membership

2015-present Member, American Society of Hematology (ASH).
2015-present Member, American Association for the Advancement of Science (AAAS).
2016-present Member, The International CML Foundation (iCMLf)
2017-present Associate Member, American Association for Cancer Research (AACR).

Honors and Awards

2009, Best Graduate Award 2009, University of Calabria, Italy, awarded for distinguished performance in biology.
2010-13, Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona, Italy.
2012, 14th ESH-iCMLf Travel Award, Baltimore, USA.
2014, 16th ESH-iCMLf Travel Award, Philadelphia, USA.
2015, Award for Best poster presentation, University of Maryland, USA.
2015, American Society of Hematology Abstract Award winner, Orlando, USA.
2017, September Postdoc Appreciation Month, University of Maryland, USA
2018, Member Memory Board and Membership Testimonial, Selected from The American Association for Cancer Research (AACR), Chicago, USA.

Professional Activities

2012, MicroFTIR stage and performing experiments at the Synchrotron Soleil, Paris, France.
2013, Organized laboratory planning and maintenance, University of Maryland, USA.
2015, Mentor laboratory for *The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research* at University of Maryland Baltimore Greenebaum CCC, Baltimore, USA
2018-present, Postdoc Peer Mentor Program, University of Maryland, USA.
2018-present Judge, *Undergraduate Poster Competition 2018*, Stevenson University and Johns Hopkins Medical Institution, Baltimore, USA. Selected by the Collaborative Teaching Fellows

Program to evaluate research posters of undergraduate students and excite them about research careers.

2019, Judge, 42nd Medical Research Day (MSRD), University of Maryland, USA.

2020, Judge, 43rd Medical Research Day (MSRD), University of Maryland, USA.

Local, National and International Services

International Service

Grant Reviewer

2021, Health Research Council of New Zealand (HRC)

Editorial Board

- Review Editor on the Editorial Board of Molecular and Cellular Oncology (specialty section of Frontiers in Oncology and Frontiers in Cell and Developmental Biology).
<https://loop.frontiersin.org/people/374295/overview>
- Review Editor on the Editorial Board of MDPI Journals.
https://www.mdpi.com/journal/jcm/submission_reviewers

Peer review activities for international journals

- Genes
- Cancers
- Journal of Clinical Medicine
- Journal of Cellular Physiology
- Oncotarget
- Frontiers in Oncology
- Healthcare
- Frontiers in Cell and Developmental Biology
- Vaccines
- Pharmaceuticals
- Blood
- International journal of cancer
- Cellular Signaling
- BioMed Research International
- Journal of Blood Medicine
- BioEssays
- Pathogens

Local and National Service

2018-present Postdoc Peer Mentor Program, University of Maryland, USA.

Teaching Service

Undergraduate Student Teaching

- 2015 Mentor laboratory for *The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research* at University of Maryland Baltimore Greenebaum CCC, Baltimore, USA.
- 2017 Mentor laboratory for *The Nathan Schnaper Summer Intern Program (NSIP) in cancer Research* at University of Maryland Baltimore Greenebaum CCC, Baltimore, USA.

Publications

Peer-reviewed journal articles

1. Bellisola G., Cinque G., Vezzalini M., Moratti E., **Silvestri G.**, Redealli S., Gambacorti Passerini C., Wehbe K., and C. Sorio. Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis, *Analyst*, 138:3934-3945, 2013.
2. Bellisola G, Bolomini Vittori M, Cinque G, Dumas P, Fiorini Z, Laudanna C, Miranda M, Sandt C, **Silvestri G**, Tomasello L, Vezzalini M, Wehbe K, Sorio C. Unsupervised explorative data analysis of normal human leukocytes and BCR/ABL positive leukemic cells mid-infrared spectra. *Analyst*, 140:4407-22, 2015.
3. Perrotti D, **Silvestri G**, Stramucci L. Chronic Myelogenous Leukemia (CML): Current Research Focus. *Haematologica*, 9:91-102, 2015.
4. Laidlaw K., Berhan S., Liu S, **Silvestri G**, Holyoake T, Frank D, Aggarwal B.B., Perrotti D., Jørgensen H., Arbiser J. Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. *Oncotarget*, 7:51651 doi: 10.18632/oncotarget.10541, 2016.
5. Perrotti D, **Silvestri G**, Stramucci L, Yu J, Trotta R. Cellular and Molecular Networks in Chronic Myeloid Leukemia: the leukemic stem, progenitor and stromal cell interplay. *Current drug targets*, 18:377-388, 2017
6. Srutova K, Curik N, Burda P, Savvulidi F, **Silvestri G**, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D and Machova Polakova K. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and resistance in chronic myeloid leukemia. *Haematologica*, 103(12):2016-2025. doi: 10.3324/haematol.2018.193086, 2018.
7. **Silvestri Giovannino**, Rossana Trotta, Lorenzo Stramucci, Justin J. Ellis, Jason G. Harb, Paolo Neviani, Shuzhen Wang, Ann-Kathrin Eisfeld, Christopher J. Walker, Bin Zhang, Klara Srutova, Carlo Gambacorti-Passerini, Gabriel Pineda, Catriona H. M. Jamieson, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Philippa C. May, Alistair G. Reid, Ramiro Garzon, Denis-Claude Roy, Moutuaata M. Moutuou, Martin Guimond, Peter Hokland, Michael W. Deininger, Garrett Fitzgerald, Christopher Harman, Francesco Dazzi, Dragana Milojkovic, Jane F. Apperley, Guido Marcucci, Jianfei Qi, Katerina Machova Polakova, Ying

Zou, Xiaoxuan Fan, Maria R. Baer, Bruno Calabretta and Danilo Perrotti. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions, ***Blood Cancer Discovery***, 1:1. doi:10.1158/0008-5472. BCD-19-0039, 2020.

(Broxmeyer, Hal. “Players in Drug-Resistant Leukemia Stem/Initiating Cells and Immunity in Patients with CML in Context of Oxygen Levels: Would Collecting/ Processing Cells in Hypoxia or Additional Information? A Next Frontier of Investigation.” ***Blood Cancer Discovery*** July 1 2020 (1) (1) 13-15; DOI: 10.1158/2643-3249. BCD-20-0034 (**Silvestri G. paper spotlight in the first issue of *Blood Cancer Discovery***).

8. *Palma G, *Pasqua T, **Silvestri G**, Rocca C, Gualtieri P, Barbieri A, De Bartolo A, De Lorenzo A, Angelone T, Avolio E and Botti G. PI3K δ Inhibition as a Potential Therapeutic Target in COVID-19, ***Frontiers in Immunology***, 11:2094. doi: 10.3389/fimmu.2020.0209, 2020. *equally contributed.

Submitted or In-Revision Peer-reviewed journal articles

Benedetti*, F.; **Silvestri***, G.; Nartuhi*, C.M.; Weichseldorfer, M.; Cash, M.N.; Dulcey, M.; Vittor, A.Y.; Ciccozzi, M.; Salemi, M.; Latinovic, O.S.; et al. Retinoic acid stimulation of human neuronal cells increases SARS-CoV-2 receptors expression and Spike-mediated entry. ***Microorganisms***, *equally contributed (under review) 2021.

Major Invited Speeches

National

1. **Silvestri, G.**, MicroRNAs as regulators of stem and progenitor CML cells function, ESH-iCMLf, Philadelphia, 2014.
2. **Silvestri, G.**, Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML, 57th ASH, Orlando, 2015.

International

1. **Silvestri, G.**, The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. ESH-iCMLf, Estoril, Portugal, 2017.

Proffered Communications: oral (O) and poster (P) poster presentation

1. Morsi H., El Ayoubi H., Moratti E., Vezzalini M., **Silvestri G.**, Stradoni R., Murineddu M., Gabbas A., Monne M. and C. Sorio. High Resistance Rate of Chronic Myeloid Leukaemia (CML) to Imatinib Myselate (IM) Might be related to Protein Tyrosine Phosphatase Receptor Type Gamma (PTPRG) Down-Regulation. *Proceedings Qatar Foundation Annual Research Forum Epub: November 2011* (O).

2. Bellisola G., Cinque G., Vezzalini M., **Silvestri G.**, Redaelli S., Gambacorti Passerini C., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier Transform InfraRed microspectroscopy (microFTIR) and unsupervised Hierarchical Cluster Analysis (HCA) *Proceeding of the Synchrotron Radiation User Meeting Oxford, UK, September 2012.* (P).
3. **Silvestri G***, Mirenda M., Vezzalini M., Moratti E., Laudanna C. and C. Sorio. Molecular mechanisms of the antiproliferative effect of Protein Tyrosine Phosphatase Receptor-like Gamma (PTPRG): BCR/ABL and LYN kinase as key targets. *Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy.* Baltimore, Usa, September 2012 (P) (*): recipient of the iCMLF travel award.
4. Bellisola G., Cinque G., Vezzalini M., Moratti E., **Silvestri G.**, Redaelli S., Wehbe K. and C. Sorio. Rapid identification of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy (microFTIR) and unsupervised pattern recognition. *Proceeding of the 14th ESH-iCMLf International Conference on CML Biology and Therapy.* Baltimore, USA, September 2012 (P).
5. Bellisola G., Cinque G., Sandt C., Dumas P., **Silvestri G.** and C. Sorio. Oncosuppressive effect of direct transduction of receptor-type tyrosine-protein phosphatase gamma (PTPRG) intracellular catalytic domains in K562 cells. *Proceeding of the 15th ESH-iCMLf International Conference on CML Biology and Therapy.* Estoril, Portugal, September 2013 (P).
6. Tomasello L., **Silvestri G.**, Della Peruta M., Fiorini Z., Vezzalini M. and Claudio Sorio. Protein Tyrosine Phosphatase Receptor Type Gamma is an inhibitor of critical BCR/ABL driven pathways in Chronic Myeloid Leukemia. *Societa' Italiana di Cancerologia.* Ferrara, Italy, September 2014 (O).
7. Bellisola G., Tomasello L., Fiorini Z., **Silvestri G.**, Vezzalini M. and Claudio Sorio. Direct transduction of Receptor-Type Protein Tyrosine-Phosphatase Gamma (PTPRG) intracellular catalytic domains in K562 cells. *Societa' Italiana di Cancerologia.* Ferrara, Italy, September 2014 (P).
8. **Silvestri G***, Ellis J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Reid A., Milojkovic D., Apperley J., Baer M., Trotta R., and D. Perrotti. MicroRNAs as regulators of stem and progenitor CML cells function. Peer reviewed and printed in the Proceedings of the 2014 *ESH-iCMLf International Conference on CML-Biology and Therapy*, Philadelphia (O). (*): Invited Speaker.
9. **Silvestri G.**, Ellis J.J., Stramucci L., Harb J.G., Neviani P., Marcucci G., Roy D-C., Hokland P., Milojkovic D., Reid A., Apperley J.F., Livak F.M., Baer M.R., Trotta R., and D. Perrotti. miR-300 acts as a tumor suppressor in Ph⁺ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. Peer Reviewed and Published in Blood (Suppl.) dedicated to the 56th *ASH Annual Meeting 2014* (P).
10. **Silvestri G***, Justin Ellis, Lorenzo Stramucci, Jason G Harb, Paolo Neviani, Guido Marcucci, Denis-Claude Roy, Peter Hokland, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M. Livak, Maria R. Baer, Rossana Trotta, and Danilo Perrotti. miR-300 acts as a tumor suppressor in Ph⁺ progenitors by Modulating the JAK2-SET/PP2A-B catenin interplay. *UMB Cancer Center Retreat*, Baltimore, USA, May 18, 2015. (P) (*): Best Poster Presentation.

11. **Silvestri G***, Stramucci L, Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger MW., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R. and Perrotti D. Role of the MSC-derived exosomal and endogenous JAK2-SET/PP2A-beta-catenin-modulator miR-300 in leukemic stem/progenitor and NK cell proliferation and survival in CML. Peer reviewed and printed in the Proceedings of the 2015 *ESH-iCMLf International Conference on CML-Biology and Therapy*, Estoril, Portugal (O).
(*): Best scored Biology Abstract.
12. **Silvestri G***, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C, Hokland P., Deininger MW., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in *Blood (Suppl.)* dedicated to the 57th *ASH Annual Meeting 2015* (O). (*): ASH travel award.
13. Trotta R., **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger M.W., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., and Perrotti D. Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. *Proceeding of the AACR Annual Meeting* (New Orleans, LA) 2016 (P).
14. **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Marcucci G., Srutova K., Machova Polakova K., Roy D-C., Hokland P., Deininger M.W., Bhatia R., Gambacorti-Passerini C., Milojkovic D., Reid A.G., Apperley J.F., Livak F., Baer M.R., Trotta R., and Perrotti D. Role of Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Peer Reviewed and Published in the *Haematologica (Suppl.)* dedicated to the *European Hematology Association (EHA) Annual Meeting*. Copenhagen, Denmark. 2016. (O).
15. Yu J.E., **Silvestri G.**, Stramucci L., Livak F.M., Baer M.R., Trotta R., and Perrotti, D. The Role of SETBP1 in Leukemia-Initiating Cell Survival and Self-Renewal in Adult Ph⁺ B-ALL. *ESH-iCMLf International Conference on CML-Biology and Therapy*, Houston TX Sept. 2016 (O).
16. Yu J.E., **Silvestri G.**, Stramucci L., Sanada M., Yamaguchi T., Du Y., Westermarck J., Caligiuri M.A., Garzon R., Milojkovic D., Apperley J.F., Roy D-C., Marcucci G., Calabretta, B., Baer M.R., Trotta R. and Perrotti D. Potential Targeting Ph⁺ Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 –Mediated Suppression of PP2A Activity. Peer Reviewed and Published in *Blood (Suppl.)* dedicated to the 58th *ASH Annual Meeting 2016* (P).
17. P. Burda, N. Čuřík, K. Šrūtová, F. Savvulidi, **G. Silvestri**, H. Klamová, P. Pecherková, Ž. Sovová, J. Koblihová, T. Stopka, D. Perrotti, K. Machová Poláková, Myc-dependent repression mechanism of the mir-150 transcriptional regulation in chronic myeloid leukemia. Peer Reviewed and Published in the *Leukemia (Suppl.)* dedicated to the *European Hematology Association (EHA) Annual Meeting*. Madrid, Spain. 2017 (P).

18. **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. *UMB CCC Retreat*, September 2017 (P).
19. **Silvestri G***., Stramucci L., Ellis J., Yu J., Harb JG, Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., , Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The BM Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. *ESH-iCMLf International Conference on CML-Biology and Therapy*, Estoril, Portugal Oct. 2017 (O). (*): selected for Key note lecture.
20. **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity. Peer Reviewed and Published in *Blood (Suppl.)* dedicated to the 59th *ASH Annual Meeting* 2017 (O).
21. **Silvestri G.**, Stramucci L., Ellis J., Yu J., Harb J.G., Neviani P., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C., Calabretta B., Stagno F., Vigneri P., Nteliopoulos G., May P., Reid A.G., Garzon R., Roy D-C., Guimond M., Hokland P., Deininger M., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J.F., Marcucci G., Qi J., Fan X., Machova-Polakova K., Baer M.R., Trotta R., and Perrotti D. The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. *Proceeding of the AACR Annual Meeting* (Chicago, IL) 2018 (P).
22. Trotta R., **Silvestri G.**, Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity. *Proceeding of the AACR Annual Meeting* (Chicago, IL) 2018 (P).
23. Trotta R., **Silvestri G.**, Stramucci L., Guimond M., Marcucci G., Fan X., Baer M.R., and D. Perrotti. Bone marrow microenvironment-induced miR-300 expression impairs natural killer cell proliferation and anti-tumor activity. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 81():63, DOI: 10.1097/01.qai.0000558015.84504.53, 2019. (P)
24. **Silvestri G. et al.** The 14q32.31 MIR300 DLK1-DIO3 oncosuppressor induces CML and AML cancer stem cell quiescence and inhibits NK cell Immunity. 21st *ESH-iCMLf*

International Conference on CML-Biology and Therapy, Bordeaux, France, September. 2019 (O). (*): selected abstract.

25. **Giovannino Silvestri**, Rossana Trotta, Lorenzo Stramucci, Shuzhen Wang, Ann-Kathrin Einfeld, Bin Zhang, Klara Srutova, Gabriel Pineda, Catriona Jamieson, Fabio Stagno, Paolo Vigneri, Georgios Nteliopoulos, Martin Guimond, Peter Hokland, Michael W Deininger, Francesco Dazzi, Dragana Milojkovic, Jane Apperley, Guido Marcucci, Xiaoxuan Fan, Maria R Baer, Bruno Calabretta, Danilo Perrotti. A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis by Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity. *Blood, The Journal of the American Society of Hematology*. (2019) 134 (Supplement_1): 4141. (P)
26. Francesca Benedetti*, **Giovannino Silvestri***, Saman Saadat, Frank Denaro, Olga S. Latinovic, Harry Davis, Sumiko Williams, Josph Bryant, Chozha V. Rathinam, Robert C. Gallo, Davide Zella. Characterization of a Mycoplasma DnaK Transgenic Mouse. *World Microbe Forum*, online worldwide, 2021. *equally contributed.

Grants and contract

Completed Research Support

1. 2010-2013, Ph.D. Student Fellowship, Italian Ministry of Health, University of Verona, Italy (PI: Silvestri).